Selumetinib gets the U.S. Breakthrough Therapy Designation Selumetinib- an investigational drug, for the treatment of pediatric patients aged three years and above suffering from symptomatic and/or progressive, inoperable neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN)- a rare genetic condition, has...
Find MoreEpic Sciences garners USD 52 Million for blood tests in cancer patients Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour cells while characterizing the immune response of the body at the same time. The Cancer...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.